A new study led by McGill University researchers shows that the human papillomavirus (HPV) screening test is far more accurate than the traditional Pap test in detecting cervical cancer.

World Vaccine Congress: A first-in-man trial of a live Listeria vaccine was reported by Advaxis Inc. (OTCBB: ADXS - News). The Phase I/II trial was testing Lovaxin C in advanced cervical cancer patients. Lovaxin C is being developed by Advaxis as an immunotherapy that is intended to treat patients with cancers that result from human papilloma virus (HPV), including cervical cancer and head and neck cancer.

The decline in cervical cancer is a success story of cancer research. Although there are reasons to be optimistic about even further decreases in cervical cancer incidence, there still remain some women who are not screened.

It doesn't matter how small or large it is, if a cervical tumor glows brightly in a PET scan, it's apt to be more dangerous than dimmer tumors. That's the conclusion of a new study of cervical cancer patients at Washington University School of Medicine in St. Louis.

In this Research letter, Dr. Gina Ogilvie and colleagues investigate the feasibility of self-collection of specimens for HPV testing among women who may not make full use of cytology screening programs (e.g., women who are homeless or who are involved in the sex trade) and are thus at increased risk of cervical cancer.

The variety of human papilloma viruses that cause invasive cervical cancer cases worldwide are largely consistent across continents, according to a new study from the University of North Carolina at Chapel Hill.

A second cervical cancer vaccine has passed a key clinical trial and its maker is seeking to use the vaccine in countries around the world. As VOA's Carol Pearson reports, more women may be able to use this new vaccine by drug giant GlaxoSmithKline than use the first cervical cancer vaccine, Gardisil.

A new computerised screening test for cervical cancer detects more abnormalities than the traditional smear test, according to a study published on bmj.com today.

Just under 150 Perth women have contributed to major international research at the Telethon Institute for Child Health Research that has proved that the new Cervarix vaccine provides broader protection against cervical cancer.

New vaccines are available to make significant gains against cervical cancer deaths and debilitating pain from shingles, but infectious diseases experts warn that their full potential will not be realized without changes in the way vaccines for adults and adolescents are promoted, financed, and delivered in the United States.

Cervical cancer is a major problem in Vanuatu and other developing nations but lack of funding prevents women from having routine PAP smears.

Around half a million new cases of cervical cancer are diagnosed worldwide each year, resulting in a quarter of a million deaths, second only to breast cancer in women.